Utatrectinib

Utatrectinib (AZD-7451) is a potent, selective and orally active Trk inhibitor. Utatrectinib blocks TrkC activation and associated tumorigenic behaviors[1].

Product Specifications

CAS Number

[1079274-94-4]

Product Name Alternative

AZD-7451

UNSPSC

12352005

Target

Trk Receptor

Type

Reference compound

Related Pathways

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/utatrectinib.html

Purity

98.72

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC(C)OC1=CC(N2C=NC3=CC=C(N[C@H](C4=NC=C(F)C=N4)C)N=C32)=NN1

Molecular Formula

C18H19FN8O

Molecular Weight

382.39

References & Citations

[1]Kozaki R, et al. Combined use of Trk inhibitor containing heterocyclic urea derivative, and other kinase inhibitor for treating cancer. WO2019049891 A1. |[2]Ivanov SV, et al. TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior. Oncogene. 2013 Aug 8;32 (32) :3698-710. |[3]Tatematsu T, et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Mol Clin Oncol. 2014 Sep;2 (5) :725-730.